Current status and prospects of management of chronic respiratory diseases

doi:10.19983/j.issn.2096-8493.2024146

Abstract

Abstract:

Chronic respiratory diseases are a group of non-communicable diseases characterized by insidious onset and protracted course, with complex etiology, high treatment costs, and poor prognosis. This review systematically analyzes the epidemiology, pathophysiological mechanisms, and clinical management strategies of major types of chronic respiratory diseases such as chronic obstructive pulmonary disease, asthma, lung cancer, and interstitial lung diseases. The paper highlights the importance of early diagnosis, discusses management challenges such as treatment adherence, individualized treatment strategies and resource allocation, and looks into the future application prospects of emerging therapeutic approaches like targeted therapy, gene therapy, and digital health technologies, aiming to provide clinicians a comprehensive perspective on disease management.

Key words: Pulmonary disease, chronic obstructive, Asthma, Lung neoplasms, Lung diseases, interstitial, Epidemiologic study characteristics as topic, Health services administration

CLC Number:

R714.253

Zhu Yixing, Chang De. Current status and prospects of management of chronic respiratory diseases[J]. Journal of Tuberculosis and Lung Disease , 2024, 5(6): 567-572. doi: 10.19983/j.issn.2096-8493.2024146

References 32

[1]	Nugent R. Preventing and managing chronic diseases. BMJ, 2019, 364: l459. doi:10.1136/bmj.l459.
[2]	Institute for Health Metrics and Evaluation. Global Burden of Disease (GBD) 2024. Washington: Institute for Health Metrics and Evaluation, 2024.
[3]	Christenson SA, Smith BM, Bafadhel M, et al. Chronic obstructive pulmonary disease. Lancet, 2022, 399(10342): 2227-2242. doi:10.1016/S0140-6736(22)00470-6. pmid: 35533707
[4]	Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990—2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859): 2163-2196. doi:10.1016/S0140-6736(12)61729-2.
[5]	薛敏, 魏小玲, 刘苗, 等. 儿童哮喘起病年龄相关影响因素分析. 结核与肺部疾病杂志, 2024, 5(5): 468-475. doi:10.19983/j.issn.2096-8493.2024089.
[6]	时旭, 陈如冲, 李靖. 哮喘表型和2型炎症哮喘研究进展. 结核与肺部疾病杂志, 2024, 5(5): 489-494. doi:10.19983/j.issn.2096-8493.2024107.
[7]	Porsbjerg C, Melén E, Lehtimäki L, et al. Asthma. Lancet, 2023, 401(10379): 858-873. doi:10.1016/S0140-6736(22)02125-0.
[8]	Olson AL, Patnaik P, Hartmann N, et al. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis. Adv Ther, 2021, 38(7): 4100-4114. doi:10.1007/s12325-021-01786-8. pmid: 34156606
[9]	Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung Diseases. N Engl J Med, 2020, 383(10): 958-968. doi:10.1056/NEJMra2005230.
[10]	Çolak Y, Afzal S, Nordestgaard BG, et al. Importance of Early COPD in Young Adults for Development of Clinical COPD: Findings from the Copenhagen General Population Study. Am J Respir Crit Care Med, 2021, 203(10):1245-1256. doi:10.1164/rccm.202003-0532OC.
[11]	Annesi-Maesano I, Maesano CN, Biagioni B, et al. Call to action: Air pollution, asthma, and allergy in the exposome era. J Allergy Clin Immunol, 2021, 148(1): 70-72. doi:10.1016/j.jaci.2021.05.026. pmid: 34238507
[12]	Cottin V, Wollin L, Fischer A, et al. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev, 2019, 28(151): 180100. doi:10.1183/16000617.0100-2018.
[13]	Singh D, Agusti A, Anzueto A, et al. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J, 2019, 53(5): 1900164. doi:10.1183/13993003.00164-2019.
[14]	Global Initiative for Asthma. USE GRDFP. Geneva: Global Initiative for Asthma, 2023.
[15]	Singh SJ, Baldwin MM, Daynes E, et al. Respiratory sequelae of COVID-19: pulmonary and extrapulmonary origins, and approaches to clinical care and rehabilitation. Lancet Respir Med, 2023, 11(8): 709-725. doi:10.1016/S2213-2600(23)00159-5. pmid: 37216955
[16]	Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet, 2017, 389(10082): 1941-1952. doi:10.1016/s0140-6736(17)30866-8. pmid: 28365056
[17]	National Institute for Health and Care Excellence. Asthma: diagnosis, monitoring and chronic asthma management. London: National Institute for Health and Care Excellence, 2021.
[18]	Nici L, Mammen MJ, Charbek E, et al. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med, 2020, 201(9): e56-e69. doi:10.1164/rccm.202003-0625ST.
[19]	Dasgupta S, Ghosh N, Bhattacharyya P, et al. Metabolomics of asthma, COPD, and asthma-COPD overlap: an overview. Crit Rev Clin Lab Sci, 2023, 60(2): 153-170. doi:10.1080/10408363.2022.2140329.
[20]	Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer. Lancet, 2021, 398(10299): 535-554. doi:10.1016/s0140-6736(21)00312-3. pmid: 34273294
[21]	Vogelmeier CF, Román-Rodríguez M, Singh D, et al. Goals of COPD treatment: Focus on symptoms and exacerbations. Respir Med, 2020, 166: 105938. doi:10.1016/j.rmed.2020.105938.
[22]	Khan M, Cole AG, Mannino DM. Precision medicine in chronic obstructive pulmonary disease: how far have we come?. Curr Opin Pulm Med, 2022, 28(2): 115-120. doi:10.1097/mcp.0000000000000837.
[23]	MacLeod M, Papi A, Contoli M, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. Respirology, 2021, 26(6): 532-551. doi:10.1111/resp.14041. pmid: 33893708
[24]	Nagase H, Suzukawa M, Oishi K, et al. Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy. Allergol Int, 2023, 72(1): 11-23. doi:10.1016/j.alit.2022.11.008. pmid: 36543689
[25]	Vijverberg SJH, Farzan N, Slob EMA, et al. Treatment response heterogeneity in asthma: the role of genetic variation. Expert Rev Respir Med, 2018, 12(1): 55-65. doi:10.1080/17476348.2018.1403318.
[26]	Sui H, Xu X, Su Y, et al. Gene therapy for cystic fibrosis: Challenges and prospects. Front Pharmacol, 2022, 13: 1015926. doi:10.3389/fphar.2022.1015926.
[27]	朋毛措, 谢俊刚. 免疫细胞在慢性阻塞性肺疾病并发心血管疾病中的研究进展. 结核与肺部疾病杂志, 2024, 5(2): 179-185. doi:10.19983/j.issn.2096-8493.20230118.
[28]	Mattison G, Canfell O, Forrester D, et al. The Influence of Wearables on Health Care Outcomes in Chronic Disease: Systematic Review. J Med Internet Res, 2022, 24(7): e36690. doi:10.2196/36690.
[29]	Zemelka-Wiacek M, Agache I, Akdis CA, et al. Hot topics in allergen immunotherapy, 2023: Current status and future perspective. Allergy, 2024, 79(4): 823-842. doi:10.1111/all.15945.
[30]	Rowan C, Hirten R. The future of telemedicine and wearable technology in IBD. Curr Opin Gastroenterol, 2022, 38(4): 373-381. doi:10.1097/mog.0000000000000845.
[31]	Lim DSC, Kwok B, Williams P, et al. The Impact of Digital Technology on Self-Management in Cancer: Systematic Review. JMIR Cancer, 2023, 9: e45145. doi:10.2196/45145.
[32]	Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med, 2020, 288(5): 518-536. doi:10.1111/joim.13141.